Skip to main content
Equibles
ATRA logo

ATRA · Atara Biotherapeutics, Inc.

Track ATRA — free

Use ATRA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$9.44 +0.42 (+4.66%) At close · Sep 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”
View the 10-Q filed Aug 12, 2026
Market Cap
$94.76M
Shares
10.04M

ATRA metrics

60 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.44
Market cap
$94.76M

Price action

19 metrics
Price change (1W)
-8.3%
Price change (30D)
+5.5%
Price change (3M)
-8.9%
Price change (6M)
+66.4%
Price change (YTD)
-50.1%
Price change (1Y)
-25.1%
Trailing year
Price change (5Y)
—
52-week high
$18.09
52-week low
$4.18
Change from 52-week high
-50.1%
Change from 52-week low
+115.8%
Annualized volatility
143.8%
Beta
1.3
RSI (14D)
50.0
Price vs SMA 50
-1.7%
Price vs SMA 200
+1.6%
Avg volume (3M)
68,128
Relative volume
0.8
Average dollar volume
$640,109

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
10.04M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
14.4×
reciprocal yield 6.9%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-18.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2023-11-01

Profitability

9 metrics
Gross margin
—
Operating margin
-229.7%
Trailing 12 months
Net margin
-269.4%
Gross profit (TTM)
—
Operating profit (TTM)
−$14.23M
Net income (TTM)
−$16.69M
Trailing 12 months
Diluted EPS (TTM)
$-1.73
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-22.94

Growth

11 metrics
Revenue growth YoY
-96.4%
Year over year
Net income growth YoY
-302.5%
Revenue (TTM)
$6.19M
Trailing 12 months
EPS growth YoY
-268.4%
Shares change YoY
+22.1%
Year over year · more shares
Revenue CAGR (3Y)
+23.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-79.4%
Debt / equity
—
Current ratio
2.0
EBITDA (TTM)
−$14.10M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
-5.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$9.87M
Latest balance sheet
Cash & equivalents
$3.22M
Total assets
$21.02M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$21.89M
Capital expenditures (TTM)
$0
R&D (TTM)
$4.21M
SG&A (TTM)
—
Stock compensation (TTM)
$3.88M
R&D / revenue
68.0%
Stock compensation / revenue
62.7%

Ownership (13F)

3 metrics
13F filers
37
13F filer change QoQ
+2
Institutional ownership
44.5%

Short interest

3 metrics
Short interest
4.8%
Latest settlement · 9.2 days to cover
Days to cover
9.2d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$40,883
Insider-sentiment score
46 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1604464 CUSIP 046513206 13F (30d) 33 filings 32 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)